Currently, there are 75.80M common shares owned by the public and among those 73.81M shares have been available to trade.
The company’s stock has a 5-day price change of 18.52% and 28.74% over the past three months. ATYR shares are trading 58.87% year to date (YTD), with the 12-month market performance up to 61.15% higher. It has a 12-month low price of $1.08 and touched a high of $2.50 over the same period. ATYR has an average intraday trading volume of 453.73K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.50%, 19.99%, and 26.22% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Atyr Pharma Inc (NASDAQ: ATYR) shares accounts for 63.49% of the company’s 75.80M shares outstanding.
It has a market capitalization of $169.79M and a beta (3y monthly) value of 1.20. The earnings-per-share (ttm) stands at -$0.91. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.77% over the week and 4.89% over the month.
Earnings per share for the fiscal year are expected to increase by 5.62%, and 13.20% over the next financial year. EPS should shrink at an annualized rate of 13.00% over the next five years, compared to 43.36% over the past 5-year period.
Looking at the support for the ATYR, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on October 04, 2024, with the firm’s price target at $17. Jefferies coverage for the Atyr Pharma Inc (ATYR) stock in a research note released on September 05, 2024 offered a Buy rating with a price target of $9. Oppenheimer was of a view on July 05, 2023 that the stock is Perform, while RBC Capital Mkts gave the stock Outperform rating on October 12, 2021, issuing a price target of $22. Piper Sandler on their part issued Overweight rating on September 21, 2021.
